Movement Alert｜DUALITYBIO-B Rises 5.24% in Regular Trading, DB-1311 Combo First-Line SCLC ORR of 92.3% Continues to Catalyze

Market Focus09-18

On September 18, DUALITYBIO-B rose 5.24% in regular trading, trading at HK$194.0/share, with turnover of HK$106 million. The stock has continued its upward momentum following landmark clinical data disclosed at the World Conference on Lung Cancer.

On the news front, updated Phase Ib/II data for the company's B7-H3 ADC DB-1311/BNT324, co-developed with BioNTech, in combination with PD-L1×VEGF-A bispecific antibody Pumitamig for advanced lung cancer continues to fuel bullish sentiment. As of July 7, among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with first-line ORR at a striking 92.3%, second-line at 77.3%, and third-line and beyond at 52.4%.

The data release follows a series of positive developments, including a global R&D collaboration with Roche's Genentech involving a US$45 million upfront payment and over US$1 billion in potential milestones, as well as consecutive insider purchases by Chairman and CEO Zhu Zhongyuan. Multiple brokerages maintain bullish ratings, with UBS initiating coverage at a target price of HK$320.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103165467?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103165467","market":"hk","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Rises 5.24% in Regular Trading, DB-1311 Combo First-Line SCLC ORR of 92.3% Continues to Catalyze","media":"Market Focus","content":"<p><p>On September 18, DUALITYBIO-B rose 5.24% in regular trading, trading at HK$194.0/share, with turnover of HK$106 million. The stock has continued its upward momentum following landmark clinical data disclosed at the World Conference on Lung Cancer.</p><p>On the news front, updated Phase Ib/II data for the company's B7-H3 ADC DB-1311/BNT324, co-developed with BioNTech, in combination with PD-L1×VEGF-A bispecific antibody Pumitamig for advanced lung cancer continues to fuel bullish sentiment. As of July 7, among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with first-line ORR at a striking 92.3%, second-line at 77.3%, and third-line and beyond at 52.4%.</p><p>The data release follows a series of positive developments, including a global R&D collaboration with Roche's Genentech involving a US$45 million upfront payment and over US$1 billion in potential milestones, as well as consecutive insider purchases by Chairman and CEO Zhu Zhongyuan. Multiple brokerages maintain bullish ratings, with UBS initiating coverage at a target price of HK$320.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Rises 5.24% in Regular Trading, DB-1311 Combo First-Line SCLC ORR of 92.3% Continues to Catalyze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Rises 5.24% in Regular Trading, DB-1311 Combo First-Line SCLC ORR of 92.3% Continues to Catalyze\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-18 11:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 18, DUALITYBIO-B rose 5.24% in regular trading, trading at HK$194.0/share, with turnover of HK$106 million. The stock has continued its upward momentum following landmark clinical data disclosed at the World Conference on Lung Cancer.</p><p>On the news front, updated Phase Ib/II data for the company's B7-H3 ADC DB-1311/BNT324, co-developed with BioNTech, in combination with PD-L1×VEGF-A bispecific antibody Pumitamig for advanced lung cancer continues to fuel bullish sentiment. As of July 7, among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with first-line ORR at a striking 92.3%, second-line at 77.3%, and third-line and beyond at 52.4%.</p><p>The data release follows a series of positive developments, including a global R&D collaboration with Roche's Genentech involving a US$45 million upfront payment and over US$1 billion in potential milestones, as well as consecutive insider purchases by Chairman and CEO Zhu Zhongyuan. Multiple brokerages maintain bullish ratings, with UBS initiating coverage at a target price of HK$320.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1103165467","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103165467","pubTimestamp":1789702345,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 18, DUALITYBIO-B rose 5.24% in regular trading, trading at HK$194.0/share, with turnover of HK$106 million. The stock has continued its upward momentum following landmark clinical data...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势预警|DUALITYBIO-B常规交易上涨5.24%，DB-1311组合一线小细胞肺癌ORR 92.3%继续催化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On September 18, DUALITYBIO-B rose 5.24% in regular trading, trading at HK$194.0/share, with turnover of HK$106 million. The stock has continued its upward momentum following landmark clinical data disclosed at the World Conference on Lung Cancer.On the news front, updated Phase Ib/II data for the company's B7-H3 ADC DB-1311/BNT324, co-developed with BioNTech, in combination with PD-L1×VEGF-A bispecific antibody Pumitamig for advanced lung cancer continues to fuel bullish sentiment. As of July 7, among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with first-line ORR at a striking 92.3%, second-line at 77.3%, and third-line and beyond at 52.4%.The data release follows a series of positive developments, including a global R&D collaboration with Roche's Genentech involving a US$45 million upfront payment and over US$1 billion in potential milestones, as well as consecutive insider purchases by Chairman and CEO Zhu Zhongyuan. Multiple brokerages maintain bullish ratings, with UBS initiating coverage at a target price of HK$320.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103165467","isCrawlerRequest":true}